PAYX
42
-9
XEL
53
-4
SNA
53
-5
UNH
50
8
EXPD
39
-6
MDT
53
-3
HAL
39
-19
SIG
70
-8
SEE
42
-4
UNP
48
-5
AIG
51
-2
PNW
59
6
SYF
92
-3
NOV
45
-4
EMC
54
-16
APD
39
-6
MNST
61
-4
MHK
50
-5
MET
37
-4
ESS
57
-2
PAYX
42
-9
XEL
53
-4
SNA
53
-5
UNH
50
8
EXPD
39
-6
MDT
53
-3
HAL
39
-19
SIG
70
-8
SEE
42
-4
UNP
48
-5
AIG
51
-2
PNW
59
6
SYF
92
-3
NOV
45
-4
EMC
54
-16
APD
39
-6
MNST
61
-4
MHK
50
-5
MET
37
-4
ESS
57
-2
Financhill
Back

CytomX Therapeutics 10K Form

Sell
16

CTMX
CytomX Therapeutics

Last Price:
5.10
Seasonality Move:
-13.94%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CTMX News And Ratings

See the #1 stock for the next 7 days that we like better than CTMX

CTMX Financial Statistics

Sales & Book Value

Annual Sales: $101.21M
Cash Flow: $-22.23M
Price / Cash Flow: 0
Annual Sales: $-0.70
Price / Book: 0

Profitability

EPS (TTM): -0.02000
Net Income (TTM): $-569K
Gross Margin: $890K
Return on Equity: 0%
Return on Assets: -0.25%

CytomX Therapeutics Earnings Forecast

Key CytomX Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 1 years for CTMX is 100.00%.
  • The Selling, General & Administrative Expenses for CTMX have been equal to 29.66% of Gross Profit Margin.
  • The Research & Development expenses have been 76.75% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CTMX is -0.56% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

CytomX Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CTMX
CUSIP: 23284F
Website: cytomx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.17
Quick Ratio: 1.14

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CTMX Technical Analysis vs Fundamental Analysis

Sell
16
CytomX Therapeutics (CTMX) is a Sell

Is CytomX Therapeutics a Buy or a Sell?